AGT and metabolic syndrome: The present data demonstrated that an ARB, olmesartan, could decrease urinary excretions of albumin (Figure 3), as well as AGT (Figure 4), suggesting that an ARB has albuminuria reduction effects in patients with metabolic syndrome.